Novo Nordisk
-
{
- All
- News
- Videos
-
Novo Nordisk's Investigational Zenagamtide Shows 14.6% Weight Loss In Adults With Type-2 Diabetes
Patients taking zenagamtide saw a significant drop in their HbA1C levels. Higher doses, 40 mg, lowered HbA1C by up to 1.71 % compared to just a 0.14 drop in the placebo group.
-
Novo Nordisk Partners With OpenAI To Accelerate Drug Discovery
The company said Artificial Intelligence will be used to analyse complex datasets, identify potential drug candidates and reduce the time taken to move from research to clinical application.
-
Novo Nordisk Partners With OpenAI To Accelerate Drug Discovery
The company said Artificial Intelligence will be used to analyse complex datasets, identify potential drug candidates and reduce the time taken to move from research to clinical application.
-
FDA Approves New Weight-Loss Pill For Use At Any Time Of Day
The US regulator has approved Eli Lilly's new oral weight-loss drug Foundayo through a fast-track process, offering a more convenient and potentially affordable alternative to injectable obesity treatments.
-
Higher-Dose Wegovy Gets US Nod, Trials Show Over 20% Average Weight Loss, Says Drugmaker
Novo Nordisk said it plans to launch the new formulation, (semaglutide 7.2 mg), in the United States in April 2026.
-
Higher-Dose Wegovy Gets US Nod, Trials Show Over 20% Average Weight Loss, Says Drugmaker
Novo Nordisk said it plans to launch the new formulation, (semaglutide 7.2 mg), in the United States in April 2026.
-
What Are Semaglutide Generics? Here's Why They Matter More In India Now
Semaglutide works by imitating the natural hormone glucagon-like peptide-1 (GLP-1), which plays a key role in managing blood sugar.
-
What Are Semaglutide Generics? Here's Why They Matter More In India Now
Semaglutide works by imitating the natural hormone glucagon-like peptide-1 (GLP-1), which plays a key role in managing blood sugar.
-
Cheap Generic Ozempic To Hit India: Patent Exit Sparks Weight-Loss Drug Boom
Swati Pradhan sees about 12 obesity patients a day at her clinic in southern Mumbai. She expects this number to at least double from this month as Indian drug makers prepare to launch off-patent versions of Novo Nordisk A/S's blockbuster weight.
-
Cheap Generic Ozempic To Hit India: Patent Exit Sparks Weight-Loss Drug Boom
Swati Pradhan sees about 12 obesity patients a day at her clinic in southern Mumbai. She expects this number to at least double from this month as Indian drug makers prepare to launch off-patent versions of Novo Nordisk A/S's blockbuster weight.
-
Novo Nordisk's CagriSema Delivers 23% Weight Loss In Trial But Still Trails Eli Lilly's Tirzepatide
CagriSema is a once-weekly subcutaneous injection, which is being investigated by Novo Nordisk as a treatment for adults with overweight or obesity.
-
Novo Nordisk's CagriSema Delivers 23% Weight Loss In Trial But Still Trails Eli Lilly's Tirzepatide
CagriSema is a once-weekly subcutaneous injection, which is being investigated by Novo Nordisk as a treatment for adults with overweight or obesity.
-
Novo Nordisk Sues Telehealth Company Over 'Knock-Off' Weight Loss Drugs, Flags Patient Safety Risks
The lawsuit, filed in the US, alleges that Hims infringed Novo Nordisk's patent by mass marketing compounded semaglutide products that have not been cleared by the US Food and Drug Administration (FDA).
-
Novo Nordisk Sues Telehealth Company Over 'Knock-Off' Weight Loss Drugs, Flags Patient Safety Risks
The lawsuit, filed in the US, alleges that Hims infringed Novo Nordisk's patent by mass marketing compounded semaglutide products that have not been cleared by the US Food and Drug Administration (FDA).
-
Novo Nordisk Partners With Emcure To Launch Weight Loss Drug Poviztra In India
Emcure Pharma becomes the first Indian company to hold exclusive rights to distribute and commercialise Poviztra, a semaglutide injection 2.4 mg for weight loss, the statement said.
-
Novo Nordisk's Investigational Zenagamtide Shows 14.6% Weight Loss In Adults With Type-2 Diabetes
Patients taking zenagamtide saw a significant drop in their HbA1C levels. Higher doses, 40 mg, lowered HbA1C by up to 1.71 % compared to just a 0.14 drop in the placebo group.
-
Novo Nordisk Partners With OpenAI To Accelerate Drug Discovery
The company said Artificial Intelligence will be used to analyse complex datasets, identify potential drug candidates and reduce the time taken to move from research to clinical application.
-
Novo Nordisk Partners With OpenAI To Accelerate Drug Discovery
The company said Artificial Intelligence will be used to analyse complex datasets, identify potential drug candidates and reduce the time taken to move from research to clinical application.
-
FDA Approves New Weight-Loss Pill For Use At Any Time Of Day
The US regulator has approved Eli Lilly's new oral weight-loss drug Foundayo through a fast-track process, offering a more convenient and potentially affordable alternative to injectable obesity treatments.
-
Higher-Dose Wegovy Gets US Nod, Trials Show Over 20% Average Weight Loss, Says Drugmaker
Novo Nordisk said it plans to launch the new formulation, (semaglutide 7.2 mg), in the United States in April 2026.
-
Higher-Dose Wegovy Gets US Nod, Trials Show Over 20% Average Weight Loss, Says Drugmaker
Novo Nordisk said it plans to launch the new formulation, (semaglutide 7.2 mg), in the United States in April 2026.
-
What Are Semaglutide Generics? Here's Why They Matter More In India Now
Semaglutide works by imitating the natural hormone glucagon-like peptide-1 (GLP-1), which plays a key role in managing blood sugar.
-
What Are Semaglutide Generics? Here's Why They Matter More In India Now
Semaglutide works by imitating the natural hormone glucagon-like peptide-1 (GLP-1), which plays a key role in managing blood sugar.
-
Cheap Generic Ozempic To Hit India: Patent Exit Sparks Weight-Loss Drug Boom
Swati Pradhan sees about 12 obesity patients a day at her clinic in southern Mumbai. She expects this number to at least double from this month as Indian drug makers prepare to launch off-patent versions of Novo Nordisk A/S's blockbuster weight.
-
Cheap Generic Ozempic To Hit India: Patent Exit Sparks Weight-Loss Drug Boom
Swati Pradhan sees about 12 obesity patients a day at her clinic in southern Mumbai. She expects this number to at least double from this month as Indian drug makers prepare to launch off-patent versions of Novo Nordisk A/S's blockbuster weight.
-
Novo Nordisk's CagriSema Delivers 23% Weight Loss In Trial But Still Trails Eli Lilly's Tirzepatide
CagriSema is a once-weekly subcutaneous injection, which is being investigated by Novo Nordisk as a treatment for adults with overweight or obesity.
-
Novo Nordisk's CagriSema Delivers 23% Weight Loss In Trial But Still Trails Eli Lilly's Tirzepatide
CagriSema is a once-weekly subcutaneous injection, which is being investigated by Novo Nordisk as a treatment for adults with overweight or obesity.
-
Novo Nordisk Sues Telehealth Company Over 'Knock-Off' Weight Loss Drugs, Flags Patient Safety Risks
The lawsuit, filed in the US, alleges that Hims infringed Novo Nordisk's patent by mass marketing compounded semaglutide products that have not been cleared by the US Food and Drug Administration (FDA).
-
Novo Nordisk Sues Telehealth Company Over 'Knock-Off' Weight Loss Drugs, Flags Patient Safety Risks
The lawsuit, filed in the US, alleges that Hims infringed Novo Nordisk's patent by mass marketing compounded semaglutide products that have not been cleared by the US Food and Drug Administration (FDA).
-
Novo Nordisk Partners With Emcure To Launch Weight Loss Drug Poviztra In India
Emcure Pharma becomes the first Indian company to hold exclusive rights to distribute and commercialise Poviztra, a semaglutide injection 2.4 mg for weight loss, the statement said.
